Kristina A. Kolmakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kristina A. Kolmakova has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana E. Belokrinitskaya
Chita State Medical Academy
10 shared publications - Nataly I. Frolova
Chita State Medical Academy
9 shared publications - Evgeniya A. Shametova
Chita State Medical Academy
5 shared publications Белокриницкая Татьяна Евгеньевна
ФГБОУ ВО «Читинская государственная медицинская академия» Минздрава России
4 shared publicationsChita State Medical Academy
2 shared publications- Kristina A. Rodionova
Chita State Medical Academy
2 shared publications
Latest Publications
- Open Access
- 20 June 2024
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 9 (2) , 37-54
Outcomes of Placental Abruption Depending on Severity of Pre-Eclampsia: A Multicentre Cohort Observational Retrospective Study
Aim. Placental abruption is a severe complication of pregnancy, which is often accompanied by pre-eclampsia and early delivery. Here we aimed to study maternal and neonatal outcomes in patients with placental abruption depending on the severity of pre-eclampsia.Materials and Methods. The study included 509 patients with placental abruption and pre-eclampsia from 22 medical centers in 16 regions of the Russian Federation, which were divided into two groups: patients with placental abruption and severe pre-eclampsia (n = 369) and patients with placental abruption and moderate pre-eclampsia (n = 140).Results. Regardless of the severity of pre-eclampsia, average term of placental abruption was 34 weeks of pregnancy. Among the adverse maternal outcomes in patients with placental abruption and severe pre-eclampsia were coagulopathy (OR = 5.01; 95% CI = 1.17–21.46) and near miss proportion (OR = 2.95; 95% CI =1.22 –7.08) which were significantly more common as compared to a moderate pre-eclampsia. Neonatal outcomes were accompanied by a high perinatal mortality (12.8%) and neonatal morbidity due to a high prevalence of premature birth (65%), asphyxia (64%), and small for gestational age (40%). Groups with severe and moderate pre-eclampsia had no statistically significant differences in neonatal outcomes, excepting congenital malformations which were found less frequently (OR = 0.32; 95% CI 0.13–0.79) in severe pre-eclampsia.Conclusion. Severity of pre-eclampsia did not affect neonatal outcomes in women with placental abruption. Maternal outcomes were significantly worse in patients with severe pre-eclampsia in comparison with those with moderate pre-eclampsia.
- 20 June 2024
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 9 (2) , 37-54
Open AccessOutcomes of Placental Abruption Depending on Severity of Pre-Eclampsia: A Multicentre Cohort Observational Retrospective Study
Aim. Placental abruption is a severe complication of pregnancy, which is often accompanied by pre-eclampsia and early delivery. Here we aimed to study maternal and neonatal outcomes in patients with placental abruption depending on the severity of pre-eclampsia.Materials and Methods. The study included 509 patients with placental abruption and pre-eclampsia from 22 medical centers in 16 regions of the Russian Federation, which were divided into two groups: patients with placental abruption and severe pre-eclampsia (n = 369) and patients with placental abruption and moderate pre-eclampsia (n = 140).Results. Regardless of the severity of pre-eclampsia, average term of placental abruption was 34 weeks of pregnancy. Among the adverse maternal outcomes in patients with placental abruption and severe pre-eclampsia were coagulopathy (OR = 5.01; 95% CI = 1.17–21.46) and near miss proportion (OR = 2.95; 95% CI =1.22 –7.08) which were significantly more common as compared to a moderate pre-eclampsia. Neonatal outcomes were accompanied by a high perinatal mortality (12.8%) and neonatal morbidity due to a high prevalence of premature birth (65%), asphyxia (64%), and small for gestational age (40%). Groups with severe and moderate pre-eclampsia had no statistically significant differences in neonatal outcomes, excepting congenital malformations which were found less frequently (OR = 0.32; 95% CI 0.13–0.79) in severe pre-eclampsia.Conclusion. Severity of pre-eclampsia did not affect neonatal outcomes in women with placental abruption. Maternal outcomes were significantly worse in patients with severe pre-eclampsia in comparison with those with moderate pre-eclampsia.
- Open Access
- 4 October 2023
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 25 (3) , 341-347
POST-COVID-19-syndrome in young healthy women: myth or reality?
Aim. To assess the incidence and severity of new persistent symptoms in somatically healthy young women with and without a history of COVID-19. Materials and methods. The main study group included patients who had PCR-confirmed COVID-19 in JulyOctober 2021 (n=181); the comparison group included women without COVID-19 during this period (n=71). Inclusion criteria: female sex, age 1835 years, no pregnancy, overweight/obesity, diabetes mellitus, chronic hypertension, premenstrual syndrome, and other somatic and/or chronic infectious diseases. Post-COVID syndrome (PCS) was diagnosed based on symptoms absent before COVID-19, appeared 4 weeks from the disease onset, and lasted at least 2 months, which could not be explained by alternative diagnoses. We used primary medical records and interviewed patients using a special questionnaire to develop a statistical database. The severity of symptoms was assessed using a 10-point scale. Results. New persistent symptoms during the pandemic in young, initially somatically healthy women with and without COVID-19 were reported with similar frequency: 96.1 and 93.0%, respectively (odds ratio OR 1.88, 95% confidence interval CI 0.586.14; p2=0.327). Only patients with COVID-19 reported cough (43.6%), shortness of breath (26.5%), chest pain (18.2%), weight loss (18.8%), hair loss (60.8%); in the comparison group, these symptoms were not reported; p20.001. Patients with PCS were more likely to experience memory impairment 49.2% vs 12.7% (OR 6.66, 95% CI 3.1314.21; p20.001); headache 43.1% vs 11.3% (OR 5.96, 95% CI 2.713.17; p20.001); depression 19.9% vs 8.5% (OR 2.69, 95% CI 1.086.7; p2=0.029); myalgia 31.5% vs 8.5% (OR 4.98, 95% CI 2.0412.17; p20.001). Patients of both groups showed similar frequency of fatigue (69.0% vs 71.8%; p2=0.66), drowsiness (54.9% vs 43.6%; p2=0.11), palpitations (19.7% vs 29.8%; p2=0.1), menstrual cycle changes (22.5% vs 21.0%; p2=0.865), and skin manifestations (2.8% vs 6.6%; p2=0.24). COVID-19 survivors had a more pronounced memory impairment (4.0 vs 1.0 points; p0.001), headache (5.0 vs 3.0 points; p=0.001), myalgia (5.0 vs 1.0 points; p0.001) and less severe insomnia (3.0 vs 5.0 points; p=0.004). Conclusion. The PCS symptoms are common in initially somatically healthy women of early reproductive age. Similar symptoms in women with no history of COVID-19 may be due to post-traumatic stress anxiety disorder. Further interdisciplinary research is needed to identify the pathophysiological mechanisms for the occurrence of new persistent symptoms in different age and social groups during the COVID-19 pandemic.
- 4 October 2023
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 25 (3) , 341-347
Open AccessPOST-COVID-19-syndrome in young healthy women: myth or reality?
Aim. To assess the incidence and severity of new persistent symptoms in somatically healthy young women with and without a history of COVID-19. Materials and methods. The main study group included patients who had PCR-confirmed COVID-19 in JulyOctober 2021 (n=181); the comparison group included women without COVID-19 during this period (n=71). Inclusion criteria: female sex, age 1835 years, no pregnancy, overweight/obesity, diabetes mellitus, chronic hypertension, premenstrual syndrome, and other somatic and/or chronic infectious diseases. Post-COVID syndrome (PCS) was diagnosed based on symptoms absent before COVID-19, appeared 4 weeks from the disease onset, and lasted at least 2 months, which could not be explained by alternative diagnoses. We used primary medical records and interviewed patients using a special questionnaire to develop a statistical database. The severity of symptoms was assessed using a 10-point scale. Results. New persistent symptoms during the pandemic in young, initially somatically healthy women with and without COVID-19 were reported with similar frequency: 96.1 and 93.0%, respectively (odds ratio OR 1.88, 95% confidence interval CI 0.586.14; p2=0.327). Only patients with COVID-19 reported cough (43.6%), shortness of breath (26.5%), chest pain (18.2%), weight loss (18.8%), hair loss (60.8%); in the comparison group, these symptoms were not reported; p20.001. Patients with PCS were more likely to experience memory impairment 49.2% vs 12.7% (OR 6.66, 95% CI 3.1314.21; p20.001); headache 43.1% vs 11.3% (OR 5.96, 95% CI 2.713.17; p20.001); depression 19.9% vs 8.5% (OR 2.69, 95% CI 1.086.7; p2=0.029); myalgia 31.5% vs 8.5% (OR 4.98, 95% CI 2.0412.17; p20.001). Patients of both groups showed similar frequency of fatigue (69.0% vs 71.8%; p2=0.66), drowsiness (54.9% vs 43.6%; p2=0.11), palpitations (19.7% vs 29.8%; p2=0.1), menstrual cycle changes (22.5% vs 21.0%; p2=0.865), and skin manifestations (2.8% vs 6.6%; p2=0.24). COVID-19 survivors had a more pronounced memory impairment (4.0 vs 1.0 points; p0.001), headache (5.0 vs 3.0 points; p=0.001), myalgia (5.0 vs 1.0 points; p0.001) and less severe insomnia (3.0 vs 5.0 points; p=0.004). Conclusion. The PCS symptoms are common in initially somatically healthy women of early reproductive age. Similar symptoms in women with no history of COVID-19 may be due to post-traumatic stress anxiety disorder. Further interdisciplinary research is needed to identify the pathophysiological mechanisms for the occurrence of new persistent symptoms in different age and social groups during the COVID-19 pandemic.
- Open Access
- 14 July 2023
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 25 (2) , 183-188
Clinical characteristics and confounders of the new coronavirus infection in low-risk pregnant women: an analysis of three years of the pandemic: A cross sectional study
Background. During the three years of the new coronavirus infection (NCI) pandemic, young women of low infectious risk made a certain contribution to the severe maternal morbidity and mortality from COVID-19. Aim. To establish risk factors for morbidity and give a clinical assessment of COVID-19 during epidemic outbreaks in 2020, 2021, and 2022 in low-risk pregnant women. Materials and methods. The study included three groups of pregnant women with clinically manifested and laboratory-confirmed SARS-CoV-2 infection: 163 pregnant women who became ill in the first wave of the epidemic in October-December 2020, 158 in the second and third epidemic wave in July and October 2021, and 160 in the fourth epidemic wave in JanuaryFebruary 2022. Each comparison group included 100 pregnant women who did not become ill during the same periods of the pandemic. Patients of all groups were in the III trimester of gestation, comparable in age (1835 years), social status, parity, and body mass index, and had no known risk factors for COVID-19. Results. Iron-deficiency anemia, tobacco smoking, and belonging to the East Asian ethnic group showed a stable association with the incidence of COVID-19 in low-risk pregnant women. In the first year of the pandemic (strains zero and Alpha), the clinical presentation of NCI was dominated by a loss of smell and/or taste (87.7%), drowsiness (68.7%), and dyspnea even with a mild degree of lung damage (68.1%). The epidemics of the second year of the COVID-19 pandemic (Delta strain) were characterized by a more severe course of the disease than in the first year: fever was more often reported above 38C (19.6% vs 7.4%; p2=0.006), pneumonia confirmed by computed tomography (61.4% vs 21.4%; p20.001), severe lung damage (CT-3: 11.4% vs 4.9%; p2=0.040; CT-4: 0 vs 6.3%; p20.05), intensive care unit admission (11.4% vs 6.4%; p2=0.041); there were cases of invasive mechanical ventilation (1.89% vs 0; p2=0.118) and deaths (0.63% vs 0; p2=0.492). In the epidemic of the third year of the pandemic (Omicron strain), the COVID-19 clinical presentation was similar to seasonal acute respiratory viral infection: the predominant symptoms included runny nose (66.7%) and cough (54.4%); pneumonia was rare (3.8%). Conclusion. Iron deficiency anemia, tobacco smoking, and belonging to the East Asian ethnic group are confounders of COVID-19 disease in pregnant women without known infectious risk factors. Unlike the epidemics of the first and third year of the pandemic with dominant zero, Alpha, and Omicron strains, epidemic outbreaks of the second year of COVID-19 caused by the Delta strain were characterized by the most severe disease course, a high rate of pneumonia and deaths even in low-risk patients.
- 14 July 2023
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 25 (2) , 183-188
Open AccessClinical characteristics and confounders of the new coronavirus infection in low-risk pregnant women: an analysis of three years of the pandemic: A cross sectional study
Background. During the three years of the new coronavirus infection (NCI) pandemic, young women of low infectious risk made a certain contribution to the severe maternal morbidity and mortality from COVID-19. Aim. To establish risk factors for morbidity and give a clinical assessment of COVID-19 during epidemic outbreaks in 2020, 2021, and 2022 in low-risk pregnant women. Materials and methods. The study included three groups of pregnant women with clinically manifested and laboratory-confirmed SARS-CoV-2 infection: 163 pregnant women who became ill in the first wave of the epidemic in October-December 2020, 158 in the second and third epidemic wave in July and October 2021, and 160 in the fourth epidemic wave in JanuaryFebruary 2022. Each comparison group included 100 pregnant women who did not become ill during the same periods of the pandemic. Patients of all groups were in the III trimester of gestation, comparable in age (1835 years), social status, parity, and body mass index, and had no known risk factors for COVID-19. Results. Iron-deficiency anemia, tobacco smoking, and belonging to the East Asian ethnic group showed a stable association with the incidence of COVID-19 in low-risk pregnant women. In the first year of the pandemic (strains zero and Alpha), the clinical presentation of NCI was dominated by a loss of smell and/or taste (87.7%), drowsiness (68.7%), and dyspnea even with a mild degree of lung damage (68.1%). The epidemics of the second year of the COVID-19 pandemic (Delta strain) were characterized by a more severe course of the disease than in the first year: fever was more often reported above 38C (19.6% vs 7.4%; p2=0.006), pneumonia confirmed by computed tomography (61.4% vs 21.4%; p20.001), severe lung damage (CT-3: 11.4% vs 4.9%; p2=0.040; CT-4: 0 vs 6.3%; p20.05), intensive care unit admission (11.4% vs 6.4%; p2=0.041); there were cases of invasive mechanical ventilation (1.89% vs 0; p2=0.118) and deaths (0.63% vs 0; p2=0.492). In the epidemic of the third year of the pandemic (Omicron strain), the COVID-19 clinical presentation was similar to seasonal acute respiratory viral infection: the predominant symptoms included runny nose (66.7%) and cough (54.4%); pneumonia was rare (3.8%). Conclusion. Iron deficiency anemia, tobacco smoking, and belonging to the East Asian ethnic group are confounders of COVID-19 disease in pregnant women without known infectious risk factors. Unlike the epidemics of the first and third year of the pandemic with dominant zero, Alpha, and Omicron strains, epidemic outbreaks of the second year of COVID-19 caused by the Delta strain were characterized by the most severe disease course, a high rate of pneumonia and deaths even in low-risk patients.
- Open Access
- 1 April 2023
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 8 (1) , 32-42
COVID-19 pandemic in low-risk pregnant women in 2020-2022: disease confounders and clinical characteristics
Aim. To identify confounders and clinical symptoms of COVID-19 in low-risk pregnant women during the pandemics from 2020 to 2022.Materials and Methods. The study included pregnant women with COVID-19: 1) those who have been admitted in October-December 2020 (n = 163); 2) those who have been admitted in May-August 2021 (n = 158); 3) those who have been admitted in January-February 2022 (n = 160). Patients in all groups were in the 3st trimester of gestation and were comparable in age (18–35 years), socioeconomic status, parity, body mass index, and had no established risk factors for COVID-19.Results. Iron deficiency anemia, tobacco smoking, and belonging to the East Asian ethnic group were recognized as reliable confounders for COVID-19 in pregnant women. In the 1st year of the pandemic, the most common symptoms were: loss of smell/taste (87.7%), somnolence (68,7%), and shortness of breath (68.1%). In the 2nd pandemic year, SARS-CoV-2 Delta variant more frequently resulted in fever above 38°C (19.6% vs 7.4%), pneumonia (61.4% vs 21.4%), respiratory failure (17.7% vs 4.9%), admission to intensive care unit (11.4% vs 6.4%), and invasive mechanical ventilation (1.89% vs 0). Symptoms of COVID-19 in the 3rd year of the pandemic were similar to those observed in seasonal acute respiratory viral infections: runny nose (66.7%) and cough (54.4%), whereas the cases of pneumonia were rare (3.8%).Conclusion. Among the most reliable confounders of COVID-19 in pregnant women without any risk factors in the 3rd trimester of gestation are iron deficiency anemia, tobacco smoking, and belonging to the East Asian ethnic group. Each SARS-CoV-2 variant provoked vastly different symptoms.
- 1 April 2023
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 8 (1) , 32-42
Open AccessCOVID-19 pandemic in low-risk pregnant women in 2020-2022: disease confounders and clinical characteristics
Aim. To identify confounders and clinical symptoms of COVID-19 in low-risk pregnant women during the pandemics from 2020 to 2022.Materials and Methods. The study included pregnant women with COVID-19: 1) those who have been admitted in October-December 2020 (n = 163); 2) those who have been admitted in May-August 2021 (n = 158); 3) those who have been admitted in January-February 2022 (n = 160). Patients in all groups were in the 3st trimester of gestation and were comparable in age (18–35 years), socioeconomic status, parity, body mass index, and had no established risk factors for COVID-19.Results. Iron deficiency anemia, tobacco smoking, and belonging to the East Asian ethnic group were recognized as reliable confounders for COVID-19 in pregnant women. In the 1st year of the pandemic, the most common symptoms were: loss of smell/taste (87.7%), somnolence (68,7%), and shortness of breath (68.1%). In the 2nd pandemic year, SARS-CoV-2 Delta variant more frequently resulted in fever above 38°C (19.6% vs 7.4%), pneumonia (61.4% vs 21.4%), respiratory failure (17.7% vs 4.9%), admission to intensive care unit (11.4% vs 6.4%), and invasive mechanical ventilation (1.89% vs 0). Symptoms of COVID-19 in the 3rd year of the pandemic were similar to those observed in seasonal acute respiratory viral infections: runny nose (66.7%) and cough (54.4%), whereas the cases of pneumonia were rare (3.8%).Conclusion. Among the most reliable confounders of COVID-19 in pregnant women without any risk factors in the 3rd trimester of gestation are iron deficiency anemia, tobacco smoking, and belonging to the East Asian ethnic group. Each SARS-CoV-2 variant provoked vastly different symptoms.
- 1 January 2022
- Published by Dynasty Publishing House in Voprosy Ginekologii, Akušerstva i Perinatologii
- Vol. 21 (3)
Assessment of the effectiveness of COVID-19 preventive measures in pregnant women
Objective. To assess the effectiveness of different preventive measures for novel coronavirus infection in pregnant women. Patients and Methods. This study included 125 pregnant women hospitalized with moderate to severe laboratory-confirmed SARS-CoV-2 infection between September and November 2021 (the fourth pandemic wave), and 175 pregnant women who were not infected with COVID-19 during the same period. All women in these two groups were comparable for gestational age (II–III trimesters, 24–39 weeks), age (20–40 years), social status, parity, body mass index, and had no known COVID-19 risk factors. Results. Our findings revealed that vaccination 3-5 months before pregnancy (OR = 4.12; 95% CI 1.28–13.27; χ2 = 0.022), inconsistent use and/or non-timely replacement of face masks (OR = 5.71; 95% CI 2.83–11.51) were associated with the increased risk of COVID-19 in the second and third trimesters of gestation. It was showed that systematic (once in the morning at 24–48-hour intervals) intranasal administration of recombinant interferon alpha-2b (IFN-α; Grippferon) as compared with a single application after exposure to COVID-19 reduced the disease incidence rate and there was no evident risk of illness (OR = 0.08; 95% CI 0.05–0.14; 19.2% vs 74,3%, p < 0.001). This can be explained by the fact that women were mostly infected in unpredictable conditions (e.g., 29.2% of pregnant women were infected from family members, 23.9% had unknown source of exposure). The use of umifenovir, not currently authorised for the medication-assisted prevention of COVID-19 in pregnant women, and rectal administration of IFN-α suppositories did not reduce the disease incidence rate. Rectal use of IFN-α suppositories by pregnant women off-label increased the incidence (32.0 vs 15.4%, p = 0.001) and risk of developing novel coronavirus infection (OR = 2.58; 95% CI 1.48–4.50). Conclusion. There is a need to improve awareness among pregnant women about the mandatory and timely vaccination against COVID-19 during pregnancy and the importance of strict adherence to wearing face masks. Increased efforts should be made to monitor and inform pregnant women about the use of only authorised medication-assisted preventive measures of SARS-CoV-2 infection, such as intranasal administration of recombinant IFN α-2b (Grippferon). During the epidemic rise in COVID-19 cases, the systematic intranasal administration of recombinant interferon-based medication Grippferon (once in the morning at 24–48-hour intervals) is recommended for pregnant women. Key words: pregnancy, COVID-19, incidence rate, vaccination, recombinant interferon alpha-2b, Grippferon, prevention
- 1 January 2022
- Published by Dynasty Publishing House in Voprosy Ginekologii, Akušerstva i Perinatologii
- Vol. 21 (3)
Assessment of the effectiveness of COVID-19 preventive measures in pregnant women
Objective. To assess the effectiveness of different preventive measures for novel coronavirus infection in pregnant women. Patients and Methods. This study included 125 pregnant women hospitalized with moderate to severe laboratory-confirmed SARS-CoV-2 infection between September and November 2021 (the fourth pandemic wave), and 175 pregnant women who were not infected with COVID-19 during the same period. All women in these two groups were comparable for gestational age (II–III trimesters, 24–39 weeks), age (20–40 years), social status, parity, body mass index, and had no known COVID-19 risk factors. Results. Our findings revealed that vaccination 3-5 months before pregnancy (OR = 4.12; 95% CI 1.28–13.27; χ2 = 0.022), inconsistent use and/or non-timely replacement of face masks (OR = 5.71; 95% CI 2.83–11.51) were associated with the increased risk of COVID-19 in the second and third trimesters of gestation. It was showed that systematic (once in the morning at 24–48-hour intervals) intranasal administration of recombinant interferon alpha-2b (IFN-α; Grippferon) as compared with a single application after exposure to COVID-19 reduced the disease incidence rate and there was no evident risk of illness (OR = 0.08; 95% CI 0.05–0.14; 19.2% vs 74,3%, p < 0.001). This can be explained by the fact that women were mostly infected in unpredictable conditions (e.g., 29.2% of pregnant women were infected from family members, 23.9% had unknown source of exposure). The use of umifenovir, not currently authorised for the medication-assisted prevention of COVID-19 in pregnant women, and rectal administration of IFN-α suppositories did not reduce the disease incidence rate. Rectal use of IFN-α suppositories by pregnant women off-label increased the incidence (32.0 vs 15.4%, p = 0.001) and risk of developing novel coronavirus infection (OR = 2.58; 95% CI 1.48–4.50). Conclusion. There is a need to improve awareness among pregnant women about the mandatory and timely vaccination against COVID-19 during pregnancy and the importance of strict adherence to wearing face masks. Increased efforts should be made to monitor and inform pregnant women about the use of only authorised medication-assisted preventive measures of SARS-CoV-2 infection, such as intranasal administration of recombinant IFN α-2b (Grippferon). During the epidemic rise in COVID-19 cases, the systematic intranasal administration of recombinant interferon-based medication Grippferon (once in the morning at 24–48-hour intervals) is recommended for pregnant women. Key words: pregnancy, COVID-19, incidence rate, vaccination, recombinant interferon alpha-2b, Grippferon, prevention
- Open Access
- 26 November 2021
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 23 (5) , 421-427
Risk factors and features of COVID-19 course in pregnant women: a comparative analysis of epidemic outbreaks in 2020 and 2021
Aim. To compare risk factors, features of COVID-19 course and outcomes in pregnant women during epidemic increase in incidence in 2020 and 2021. Materials and methods. The study included 163 pregnant women with laboratory-confirmed SARS-CoV-2 infection within May December 2020 (1st2nd waves of the epidemic) and 158 pregnant women who had new coronavirus infection within May August 2021 (3rd wave of the epidemic). Patients in all groups were comparable in age (1835 years), social status, parity, body mass index, and had no known risk factors for COVID-19. Results. Iron deficiency anemia, smoking, belonging to the Buryat ethnic group were recognized as persistent risk factors for COVID-19 in pregnant women. Over the 1st year of the pandemic, in pregnant women, the following clinical manifestations of novel coronavirus infection were commonly seen: anosmia (87.7%), somnolence (68.7%), shortness of breath even with a mild lung damage (68.1%). In the 3rd wave of the 2nd year of the pandemic, the leading signs and symptoms were cough (70.3% vs 38.7%, p0.001), runny nose (46.2% vs 3.7%, p0001), sore throat (367% vs 37%, p0.001); an increase in body temperature above 38C (19.6% vs 7,4%, p=0.006), pneumonia detected by computed tomography (61.4% vs 21.4%; p0.001). There was a significant increase in the incidence of severe lung lesions (with computed tomography 34: 17.7% vs 4.9%; p0.001) and admissions to intensive care units (11.4% vs 6.4%; p= 0041). There was a need for invasive mechanical ventilation (1.89% vs 0%; p=0.118). There was 1 death (0.63% vs 0%; p= 0.492), which was associated with the fulminant course of COVID-19. Conclusion. Persistent COVID-19 confounders in pregnant women who have no known risk factors in the third trimester of gestation are iron deficiency anemia, smoking, and belonging to the Buryat ethnic group. The clinical course of SARS-CoV-2 infection has changed and became more unfavorable: symptoms of acute respiratory disease (cough, runny nose, sore throat) began to prevail, the rate and severity of pneumonia and rate of mortality increased.
- 26 November 2021
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 23 (5) , 421-427
Open AccessRisk factors and features of COVID-19 course in pregnant women: a comparative analysis of epidemic outbreaks in 2020 and 2021
Aim. To compare risk factors, features of COVID-19 course and outcomes in pregnant women during epidemic increase in incidence in 2020 and 2021. Materials and methods. The study included 163 pregnant women with laboratory-confirmed SARS-CoV-2 infection within May December 2020 (1st2nd waves of the epidemic) and 158 pregnant women who had new coronavirus infection within May August 2021 (3rd wave of the epidemic). Patients in all groups were comparable in age (1835 years), social status, parity, body mass index, and had no known risk factors for COVID-19. Results. Iron deficiency anemia, smoking, belonging to the Buryat ethnic group were recognized as persistent risk factors for COVID-19 in pregnant women. Over the 1st year of the pandemic, in pregnant women, the following clinical manifestations of novel coronavirus infection were commonly seen: anosmia (87.7%), somnolence (68.7%), shortness of breath even with a mild lung damage (68.1%). In the 3rd wave of the 2nd year of the pandemic, the leading signs and symptoms were cough (70.3% vs 38.7%, p0.001), runny nose (46.2% vs 3.7%, p0001), sore throat (367% vs 37%, p0.001); an increase in body temperature above 38C (19.6% vs 7,4%, p=0.006), pneumonia detected by computed tomography (61.4% vs 21.4%; p0.001). There was a significant increase in the incidence of severe lung lesions (with computed tomography 34: 17.7% vs 4.9%; p0.001) and admissions to intensive care units (11.4% vs 6.4%; p= 0041). There was a need for invasive mechanical ventilation (1.89% vs 0%; p=0.118). There was 1 death (0.63% vs 0%; p= 0.492), which was associated with the fulminant course of COVID-19. Conclusion. Persistent COVID-19 confounders in pregnant women who have no known risk factors in the third trimester of gestation are iron deficiency anemia, smoking, and belonging to the Buryat ethnic group. The clinical course of SARS-CoV-2 infection has changed and became more unfavorable: symptoms of acute respiratory disease (cough, runny nose, sore throat) began to prevail, the rate and severity of pneumonia and rate of mortality increased.
- Open Access
- 13 August 2021
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 23 (3) , 255-259
COVID-19 in pregnant and non-pregnant women of early reproductive age
Aim. To identify confounding factors, features of the clinical course and outcomes of COVID-19 in pregnant and non-pregnant patients of early reproductive age who have no known risk factors and premorbid background. Materials and methods. The study included 163 pregnant women in the third trimester of gestation, 100 non-pregnant women with laboratory-confirmed SARS-CoV-2 infection and 100 pregnant women who did not get sick. Patients of all groups were comparable in age (1835 years), social status, parity, body mass index, had no known risk factors for COVID-19; those who got sick were treated simultaneously. Results. Statistically significant associations were revealed between COVID-19 infection in the pregnant and iron deficiency anemia, vegetovascular dystonia, belonging to the Buryat ethnicity, and smoking. Pregnant women with COVID-19 were more likely to have no symptoms (23.3% vs 5%; p0.001) or had a mild course of the disease (58.9% vs 24%; p0.001). In non-pregnant patients, the course of infection was more often moderate (61% vs 14.7%; p0.001) or severe (10% vs 3.1%; p=0.038). Clinical manifestations of new coronavirus infection (NCV) in pregnant women were dominated by anosmia (87.7% vs 40%; p0.001), drowsiness (68.7% vs 17%; p0.001), dyspnea, even with a mild lung lesion (68.1% vs 19%; p0.001), headache (41.7% vs 24%; p=0.006), arthralgia (29.4% vs 16%; p=0.021), while fever above 38 C (7.4% vs 28%; p0.001) and cough (38.7% vs 61%; p0.001) were much less common. With computed tomography, pneumonia in pregnant women was diagnosed several times less often (21.4% vs 87.4%; p0.001). In the non-pregnant group, there was one death (1% vs 0%; p=0.201) associated with late hospitalization for severe NCI with grade 4 pulmonary involvement as shown on computed tomography. Conclusion. Confounders of COVID-19 in pregnant women who have no known risk factors in the third trimester of gestation are iron deficiency anemia, vegetovascular dystonia, belonging to the Buryat subpopulation, and smoking. In pregnant women, the main clinical symptoms of SARS-CoV-2 infection, with the exception of loss of smell, were nonspecific and characteristic of the physiological course of late gestation: drowsiness, dyspnea, joint pain. The predominance of mild or asymptomatic forms of infection, the lower incidence of pneumonia, and the absence of deaths in pregnant women suggests a more favorable course of COVID-19 NCI.
- 13 August 2021
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 23 (3) , 255-259
Open AccessCOVID-19 in pregnant and non-pregnant women of early reproductive age
Aim. To identify confounding factors, features of the clinical course and outcomes of COVID-19 in pregnant and non-pregnant patients of early reproductive age who have no known risk factors and premorbid background. Materials and methods. The study included 163 pregnant women in the third trimester of gestation, 100 non-pregnant women with laboratory-confirmed SARS-CoV-2 infection and 100 pregnant women who did not get sick. Patients of all groups were comparable in age (1835 years), social status, parity, body mass index, had no known risk factors for COVID-19; those who got sick were treated simultaneously. Results. Statistically significant associations were revealed between COVID-19 infection in the pregnant and iron deficiency anemia, vegetovascular dystonia, belonging to the Buryat ethnicity, and smoking. Pregnant women with COVID-19 were more likely to have no symptoms (23.3% vs 5%; p0.001) or had a mild course of the disease (58.9% vs 24%; p0.001). In non-pregnant patients, the course of infection was more often moderate (61% vs 14.7%; p0.001) or severe (10% vs 3.1%; p=0.038). Clinical manifestations of new coronavirus infection (NCV) in pregnant women were dominated by anosmia (87.7% vs 40%; p0.001), drowsiness (68.7% vs 17%; p0.001), dyspnea, even with a mild lung lesion (68.1% vs 19%; p0.001), headache (41.7% vs 24%; p=0.006), arthralgia (29.4% vs 16%; p=0.021), while fever above 38 C (7.4% vs 28%; p0.001) and cough (38.7% vs 61%; p0.001) were much less common. With computed tomography, pneumonia in pregnant women was diagnosed several times less often (21.4% vs 87.4%; p0.001). In the non-pregnant group, there was one death (1% vs 0%; p=0.201) associated with late hospitalization for severe NCI with grade 4 pulmonary involvement as shown on computed tomography. Conclusion. Confounders of COVID-19 in pregnant women who have no known risk factors in the third trimester of gestation are iron deficiency anemia, vegetovascular dystonia, belonging to the Buryat subpopulation, and smoking. In pregnant women, the main clinical symptoms of SARS-CoV-2 infection, with the exception of loss of smell, were nonspecific and characteristic of the physiological course of late gestation: drowsiness, dyspnea, joint pain. The predominance of mild or asymptomatic forms of infection, the lower incidence of pneumonia, and the absence of deaths in pregnant women suggests a more favorable course of COVID-19 NCI.
- Open Access
- 1 July 2021
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 6 (2) , 51-58
Prediction of severe pre-eclampsia in low-risk women
Aim. To find the predictors of severe pre-eclampsia in women without any established risk factors.Materials and Methods. We consecutively recruited 200 pregnant women (100 with severe pre-eclampsia and 100 with uncomplicated pregnancy and successful delivery). Criteria of inclusion were age from 18 to 35 years, absence of significant comorbid conditions (cardiovascular diseases, autoimmune diseases, metabolic disorders, and kidney diseases), absence of family history and past medical history of pre-eclampsia and thromboembolism, singleton pregnancy, and body mass index in the first trimester < 35 kg/m2 . We assessed allele and genotype distribution across several gene polymorphisms (ADD1-1378G>T, AGT704T>C, AGT-521C>T, AGTR1-1166A>C, AGTR2-1675G>A, NO3-894G>C, and NO3-786T>C) potentially associated with severe pre-eclampsia.Results. We found that the combination of AGTR2-1675АA and eNOS3-786СC polymorphisms (p = 0.04), bacteriuria (p < 0.001), acute respiratory infections (p = 0.011) and acute vulvovaginitis in second and third trimesters (p = 0.013), smoking (p < 0.001), and past medical history of abortions (p = 0.017) were risk factors of severe pre-eclampsia.Conclusions. Predictors of severe pre-eclampsia revealed in this study can be used in the development of personalised prognostication during pregnancy in patients without conventional risk factors of pre-eclampsia.
- 1 July 2021
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 6 (2) , 51-58
Open AccessPrediction of severe pre-eclampsia in low-risk women
Aim. To find the predictors of severe pre-eclampsia in women without any established risk factors.Materials and Methods. We consecutively recruited 200 pregnant women (100 with severe pre-eclampsia and 100 with uncomplicated pregnancy and successful delivery). Criteria of inclusion were age from 18 to 35 years, absence of significant comorbid conditions (cardiovascular diseases, autoimmune diseases, metabolic disorders, and kidney diseases), absence of family history and past medical history of pre-eclampsia and thromboembolism, singleton pregnancy, and body mass index in the first trimester < 35 kg/m2 . We assessed allele and genotype distribution across several gene polymorphisms (ADD1-1378G>T, AGT704T>C, AGT-521C>T, AGTR1-1166A>C, AGTR2-1675G>A, NO3-894G>C, and NO3-786T>C) potentially associated with severe pre-eclampsia.Results. We found that the combination of AGTR2-1675АA and eNOS3-786СC polymorphisms (p = 0.04), bacteriuria (p < 0.001), acute respiratory infections (p = 0.011) and acute vulvovaginitis in second and third trimesters (p = 0.013), smoking (p < 0.001), and past medical history of abortions (p = 0.017) were risk factors of severe pre-eclampsia.Conclusions. Predictors of severe pre-eclampsia revealed in this study can be used in the development of personalised prognostication during pregnancy in patients without conventional risk factors of pre-eclampsia.
- 1 January 2018
- Published by Krasnoyarsk State Medical University in Siberian Medical Review
- No. 2
INFECTIOUS DISEASES IN PREGNANCY AS A RISK FACTOR OF DEVELOPMENT THE HEAVY PREECLAMPSIA
- 1 January 2018
- Published by Krasnoyarsk State Medical University in Siberian Medical Review
- No. 2
INFECTIOUS DISEASES IN PREGNANCY AS A RISK FACTOR OF DEVELOPMENT THE HEAVY PREECLAMPSIA
- Open Access
- 1 January 2018
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 3 (3) , 9-14
ASSOCIATIVE CONNECTION OF INFECTIOUS AND INFLAMMATORY DISEASES IN PREGNANCY AND SEVERE PREECLAMPSIA
- 1 January 2018
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 3 (3) , 9-14
Open AccessASSOCIATIVE CONNECTION OF INFECTIOUS AND INFLAMMATORY DISEASES IN PREGNANCY AND SEVERE PREECLAMPSIA